Thyroid Gland Patents (Class 424/568)
-
Patent number: 10953074Abstract: The present invention is directed to compositions and methods for improving hearing parameters in a human (including hearing volume, hearing range and word recognition) by reversing or inhibiting damage to cochlear cells caused by toxic byproducts of oxygen metabolism. In a preferred embodiment, a pharmaceutically acceptable composition containing insulin-like growth factor one (IGF-1) and human growth hormone (HGH), or their derivatives in a 5:2 ratio by weight, is topically administered every three days in a dosage of 0.1 to 2 mcg per kilogram of body weight. The composition directly penetrates the inner ear and cochlea to provide greater regulation of sodium and potassium levels in the delicate sound-detecting hair cells. In accordance with the present invention, mean word recognition was improved by nearly 39 percent, hearing volume was improved by up to 40 dB, and the hearing range was improved above 6,000 Hz.Type: GrantFiled: January 8, 2017Date of Patent: March 23, 2021Inventor: Richard D. Lippman
-
Patent number: 8142817Abstract: A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The growth factor can be insulin, insulin-like growth factor, thyroid hormone, fibroblast growth factor, estrogen, retinoic acid, or their combinations.Type: GrantFiled: July 14, 2008Date of Patent: March 27, 2012Inventor: Vincent C. Giampapa
-
Publication number: 20110206775Abstract: In a method of treating a pharmaceutical component, a reducing substance is added to a solution of water and a pharmaceutical excipient having at least one residual reactive impurity. The reducing substance is allowed to react with the residual reactive impurity, thereby generating an inert reaction product. The any remaining amount of the reducing substance is removed from the pharmaceutical excipient. The pharmaceutical excipient is dried after the removing step.Type: ApplicationFiled: January 27, 2011Publication date: August 25, 2011Inventor: Pieter J. Groenewoud
-
Publication number: 20040213856Abstract: A composition and method for treatment of multiple myeloma and drug-resistant pneumonia are provided. The composition is a combination of natural products that stimulate immune system function and restore well-being in patients.Type: ApplicationFiled: March 17, 2003Publication date: October 28, 2004Inventor: Eric A Scheinbart
-
Patent number: 6706255Abstract: Liquid pharmaceutical compositions comprising at least one thyroid hormone, ethanol, a pH adjusting agent, and water are disclosed. The compositions may be delivered by a metered dosage delivery system such as an aerosol or pump-action spray, and are useful in the treatment of disorders associated with an impairment of thyroid hormone function in animals including human beings.Type: GrantFiled: September 13, 2002Date of Patent: March 16, 2004Assignee: Abbott GmbH & Co., KGInventors: Jeffrey Dickinson, Karrar Ahmad Khan, John Neville Hague, Alan Smith
-
Patent number: 6528059Abstract: Specific epitopic regions of thyroid peroxidase (TPO), a thyroid specific membrane autoantigen, have been identified within amino acid residues 456 to 933, 457 to 633, 513 to 633, and 633 to 933 of the protein (SEQ ID NO:2), with at least one distinct binding region within TPO located from amino acid residues 592 to 613 (SEQ ID NO:7). The identification and production of these localized epitopes/epitopic regions provide specific therapeutic reagents for administration to autoimmune thyroid disease patients.Type: GrantFiled: February 18, 1999Date of Patent: March 4, 2003Assignee: Regents of the University of MichiganInventors: James R. Baker, Jr., Ronald J. Koenig
-
Patent number: 6500925Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig45, a novel human protein expressed in thyroid. The polypeptides, and polynucleotides encoding them, may be used for detecting human disease states and chromosomal abnormalities, and as a therapeutic. The present invention also includes antibodies to the zsig45 polypeptides.Type: GrantFiled: March 10, 2000Date of Patent: December 31, 2002Assignee: ZymoGenetics, Inc.Inventors: Theresa A. Deisher, Paul O. Sheppard
-
Patent number: 6458842Abstract: There is disclosed a liquid pharmaceutical composition comprising a therapeutic agent which comprises: one or more thyroid hormone or hormones; from about 40% to about 96% ethanol by volume; a pH adjusting agent so that the measured pH of the composition is from about 9 to about 12; and from about 4% to about 50% water by volume; which has utility in the treatment of disorders associated with an impairment of the thyroid hormone function in animals including human beings. The liquid composition may be delivered by a metered dosage delivery system such as an aerosol or pump-action spray.Type: GrantFiled: July 31, 1996Date of Patent: October 1, 2002Assignee: Knoll AktiengesellschaftInventors: Jeffrey Dickinson, Karrar Ahmad Khan, John Neville Hague, Alan Smith
-
Patent number: 6123918Abstract: Compounds and samples may be screened for estrogenic, androgenic, and thyroid hormone activity simultaneously, by administering the compound or sample to larval amphibians or tissue obtained therefrom, particularly Hyperolius argus, prior to the end of metamorphosis, and observing developmental differences between the test amphibians and normal development for said amphibians.Type: GrantFiled: March 18, 1998Date of Patent: September 26, 2000Assignee: The Regents of the University of CaliforniaInventor: Tyrone B. Hayes
-
Patent number: 6054142Abstract: A biocompatible cell device having an internal foam scaffold to provide a growth surface for encapsulated cells which produce a biologically active molecule.Type: GrantFiled: August 1, 1996Date of Patent: April 25, 2000Assignee: Cyto Therapeutics, Inc.Inventors: Rebecca Li, Tyrone F. Hazlett
-
Patent number: 5928670Abstract: An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.Type: GrantFiled: November 26, 1997Date of Patent: July 27, 1999Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Peter F. Kador, Yukio Takahashi, Tomoyuki Terada, Libaniel Rodriguez, Matteo Schaffhauser
-
Patent number: 5855920Abstract: A hormone replenishment method particularly useful in maintaining the body's neuroendocrine clock at optimal levels and combating conditions associated with advancing age is disclosed. The method includes determining that the level of human growth hormone and at least two other supplemental hormones are below optimal or pre-determined physiological levels for an adult human. Once it has been established that the level of human growth hormone and at least two of certain supplemental hormones are below pre-determined physiological levels, the method includes establishing a regimen for the replenishment of the level of the deficient hormones to optimal or pre-determined physiological levels. The supplements hormones include the sex hormones, namely testosterone, progesterone, and estrogen, the pineal hormone melatonin, the adrenal hormones, namely DHEA and pregnenolone, the thyroid hormone, and the thymus hormone.Type: GrantFiled: December 13, 1996Date of Patent: January 5, 1999Inventor: Edmund Y. M. Chein
-
Patent number: 5851986Abstract: A method for promoting osteoblast proliferation or inhibiting bone resorption comprising administering to a subject in need thereof, a composition comprising High Mobility Group Protein (HMG-1) is disclosed.Type: GrantFiled: February 20, 1997Date of Patent: December 22, 1998Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Yukihiro Takada, Junichi Yamamura, Masaaki Goto, Seiichiro Aoe
-
Patent number: 5846548Abstract: A method of tumor therapy involves controlling the immune system by co-administration of a mitogenic immuno-stimulating substance and a thymomimetic substance.Type: GrantFiled: July 24, 1995Date of Patent: December 8, 1998Assignee: Bartos Patent Development & Holding Company Ltd.Inventor: Stefan Bartos
-
Patent number: 5789387Abstract: Methods of treating fungal infections are disclosed. The methods comprise administering a chitin synthesis inhibitor to a mammal in a continuous fashion so that at least a minimum effective concentration is maintained in the mammal's plasma or in a target organ. In a preferred embodiment, the administration is by continuous intravenous infusion and the fungal infection is due to Candida albicans. In another preferred embodiment, the administration is by a sustained release formulation and the fungal infection is due to Candida albicans.Type: GrantFiled: August 27, 1996Date of Patent: August 4, 1998Assignee: Shaman Pharmaceitucals, Inc.Inventors: Richard Fredrich Hector, Akram Sabouni
-
Patent number: 5738878Abstract: An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.Type: GrantFiled: June 5, 1995Date of Patent: April 14, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter F. Kador, Yukio Takahashi, Tomoyuki Terada, Libaniel Rodriguez, Matteo Schaffhauser
-
Patent number: 5560936Abstract: An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.Type: GrantFiled: October 26, 1993Date of Patent: October 1, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter F. Kador, Yukio Takahashi, Tomoyuki Terada, Libaniel Rodriguez, Matteo Schaffhauser
-
Patent number: 5449522Abstract: This invention provides an immunoenhancement or immunepotentiation therapy comprising administration of potassium, insulin, glucose and, optionally, thyroid, a cholinergic agent and bicarbonate. Therapeutic compositions comprising the above components in appropriate dosages are also provided.Type: GrantFiled: August 24, 1993Date of Patent: September 12, 1995Inventor: Albert F. Hill
-
Patent number: 5279836Abstract: A new use of calcitonin, as an active principle, is provided for the preparation of topically appliable medications in the treatment of pre-senile and senile idiopathic cataract; and a pharmaceutical composition containing elcatonin as active principle for the preparation of a collyrium.Type: GrantFiled: January 30, 1992Date of Patent: January 18, 1994Assignee: Mediator S.R.L.Inventor: Bruno J. R. Nicolaus
-
Patent number: 5198216Abstract: A composition for enhancing the performance of animals, such as horses or dogs, is composed of adrenal and pituitary raw tissue concentrates, vitamin C, bioflavonoid complex, pantothenic acid, methionine, choline, vitamin B1, vitamin B2, vitamin B6, niacinamide, magnesium, vitamin B12, folic acid and organic iodine. The composition is adapted to be orally administered to an animal, is composed of all natural substances, and the relative proportions of the components are approximately:at least 40 parts adrenal raw tissue concentrate toat least 2 parts pituitary raw tissue concentrate to30-60 parts vitamin C to20-30 parts magnesium to10-20 parts of each of pantothenic acid, methionine and choline to8-15 parts of each of niacinamide and bioflavonoid complex to1-5 parts of each of vitamins B1, B2 and B6 to0.1-1 parts organic iodine to0.05-0.5 parts folic acid.Type: GrantFiled: July 30, 1990Date of Patent: March 30, 1993Assignee: Daliff CorporationInventor: David M. McGee
-
Patent number: 5168102Abstract: The body composition of poultry is improved by a hormonal strategy that includes the step ofincreasing plasma levels of thyroid hormone to about 150-250% (normal endogeneous T.sub.3 hormone level=100%) during essentially the finishing phase (e.g., for chickens, 3 to 6 or 7 weeks-of-age) by administering (preferably orally) a metabolically-active thyroid hormone of the formula: ##STR1## wherein X is O, S, or CH.sub.2.Z is C.sub.2 -C.sub.4 alkylene or amino-substituted C.sub.2 -C.sub.4 alkylene,M.sup.+ is a physiologically acceptable cation, R.sub.3 and R.sub.5 are H or iodo, at least one of them being iodo,R.sub.3 ' and R.sub.5 ' are iodo, or hydrogen or --A--COO--M.sup.30 , where A is C.sub.2 -C.sub.4 alkylene and M.sup.30 is a physiologically acceptable cation,provided, that when R.sub.3 ', R.sub.5 ', R.sub.3 and R.sub.5 are all iodo, then Z--COO-- is the residue of the anion of acetic or propionic acid.Type: GrantFiled: September 14, 1990Date of Patent: December 1, 1992Assignee: University of DelawareInventor: Larry A. Cogburn
-
Patent number: 5162302Abstract: The body composition of poultry is improved by a hormonal strategy that includes the steps of(a) increasing plasma levels of thyroid hormone to at least about 150% (normal endogenous T.sub.3 hormone level=100%) during essentially the finishing phase (e.g., for chickens, 3 to 6 or 7 weeks-of-age) by administering (preferably orally) a metabolically-active thyroid hormone of the formula: ##STR1## wherein X is O, S, or CH.sub.2. Z is C.sub.2 -C.sub.4 alkylene or amino-substituted C.sub.2 -C.sub.4 alkylene,M.sup.+ is a physiologically acceptable cation,R.sub.3 and R.sub.5 are H or iodo, at least one of them being iodo,R.sub.3 ' and R.sub.5 ' are iodo, or hydrogen or --A--COO--M.sup.+, where A is C.sub.2 -C.sub.4 alkylene and M.sup.+ is a physiologically acceptable cation,provided, that when R.sub.3 ', R.sub.5 ', R.sub.3 and R.sub.Type: GrantFiled: September 14, 1990Date of Patent: November 10, 1992Assignee: University of DelawareInventor: Larry A. Cogburn
-
Patent number: 5057324Abstract: A physiologically active substance is extracted from infected tissues inoculated with a poxvirus. The novel substance of the present invention has inhibitory action against the formation of kallikrein, thus is useful as drugs such as antiinflammatory, analgesic and antiallergic agents.Type: GrantFiled: July 20, 1988Date of Patent: October 15, 1991Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Yoji Shibayama, Yoshio Toyomaki
-
Patent number: 4985254Abstract: The present invention relates to physiologically active substances extracted from infected tissues inoculated with a poxvirus. The substances of the present invention have excellent actions to improve blood flow and recover functions of diseased tissues, thus are useful as drugs for various diseases caused by blood flow disorders.Type: GrantFiled: November 3, 1988Date of Patent: January 15, 1991Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventor: Jin-emon Konishi